|
Thrombolysis
Citations 461-470 of 839 total displayed.
|
Past content
(since Jan 1999):
|
- Original Contributions
Applying a Phase II Futility Study Design to Therapeutic Stroke Trials
- Yuko Y. Palesch, Barbara C. Tilley, David L. Sackett, Karen C. Johnston, and Robert Woolson
Stroke 2005;36:2410-2414; published online before print as doi:10.1161/01.STR.0000185718.26377.07
[Abstract]
[Full text]
- Original Contributions
Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old ( 80 Years) Stroke Patients
- Jörg Berrouschot, Joachim Röther, Jörg Glahn, Thomas Kucinski, Jens Fiehler, and Götz Thomalla
Stroke 2005;36:2421-2425; published online before print as doi:10.1161/01.STR.0000185696.73938.e0
[Abstract]
[Full text]
- Research Reports
Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke
- Eric E. Smith, Abdul R. Abdullah, Iva Petkovska, Eric Rosenthal, Walter J. Koroshetz, and Lee H. Schwamm
Stroke 2005;36:2497-2499; published online before print as doi:10.1161/01.STR.0000185798.78817.f3
[Abstract]
[Full text]
- Research Reports
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
- Bart M. Demaerschalk and Todd R. Yip
Stroke 2005;36:2500-2503; published online before print as doi:10.1161/01.STR.0000185699.37843.14
[Abstract]
[Full text]
- Articles
Presence of Early Ischemic Changes on Computed Tomography Depends on Severity and the Duration of Hypoperfusion. A Single Photon Emission-Computed Tomographic Study
- Teruyuki Hirano, Toshiro Yonehara, Yuichiro Inatomi, Yoichiro Hashimoto, and Makoto Uchino
Stroke published October 27, 2005, doi:10.1161/01.STR.0000189990.31225.82
[Abstract]
- Articles
Applying a Phase II Futility Study Design to Therapeutic Stroke Trials
- Yuko Y. Palesch, Barbara C. Tilley, David L. Sackett, Karen C. Johnston, and Robert Woolson
Stroke published October 13, 2005, doi:10.1161/01.STR.0000185718.26377.07
[Abstract]
- Articles
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
- Bart M. Demaerschalk and Todd R. Yip
Stroke published October 13, 2005, doi:10.1161/01.STR.0000185699.37843.14
[Abstract]
- Articles
Revascularization End Points in Stroke Interventional Trials. Recanalization Versus Reperfusion in IMS-I
- Pooja Khatri, Joddi Neff, Joseph P. Broderick, Jane C. Khoury, Janice Carrozzella, Thomas Tomsick for the IMS-I Investigators
Stroke published October 13, 2005, doi:10.1161/01.STR.0000185698.45720.58
[Abstract]
- Articles
Thrombolysis Beyond the Guidelines. Two Treatments in One Subject Within 90 Hours Based on a Modified Magnetic Resonance Imaging Brain Clock Concept
- Raffi Topakian, Franz Gruber, Franz A. Fellner, Hans-Peter Haring, and Franz T. Aichner
Stroke published October 6, 2005, doi:10.1161/01.STR.0000185799.22645.8a
[Abstract]
- Articles
Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke
- Eric E. Smith, Abdul R. Abdullah, Iva Petkovska, Eric Rosenthal, Walter J. Koroshetz, and Lee H. Schwamm
Stroke published October 6, 2005, doi:10.1161/01.STR.0000185798.78817.f3
[Abstract]
|
|
